Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study.
Schettini F, Brasó-Maristany F, Pascual T, Lorman-Carbó N, Nucera S, Bergamino M, Galván P, Conte B, Seguí E, García Fructuoso I, Gómez Bravo R, Rodríguez AB, Martínez-Sáez O, Chic N, Vidal M, Adamo B, González-Farre B, Sanfeliu E, Cebrecos I, Mensión E, Oses G, Locci M, Mollà M, Ganau S, Jares P, Vidal-Sicart S, Muñoz M, Prat A. Schettini F, et al. Among authors: chic n. ESMO Open. 2024 Dec;9(12):103989. doi: 10.1016/j.esmoop.2024.103989. Epub 2024 Nov 27. ESMO Open. 2024. PMID: 39608304 Free PMC article.
Hormone receptor-positive early breast cancer in young women: A comprehensive review.
Walbaum B, García-Fructuoso I, Martínez-Sáez O, Schettini F, Sánchez C, Acevedo F, Chic N, Muñoz-Carrillo J, Adamo B, Muñoz M, Partridge AH, Bellet M, Brasó-Maristany F, Prat A, Vidal M. Walbaum B, et al. Among authors: chic n. Cancer Treat Rev. 2024 Sep;129:102804. doi: 10.1016/j.ctrv.2024.102804. Epub 2024 Jul 14. Cancer Treat Rev. 2024. PMID: 39084152 Review.
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer.
Lorman-Carbó N, Martínez-Sáez O, Fernandez-Martinez A, Galván P, Chic N, Garcia-Fructuoso I, Rodríguez A, Gómez-Bravo R, Schettini F, Blasco P, Castillo O, González-Farré B, Adamo B, Vidal M, Muñoz M, Perou CM, Malumbres M, Gavilá J, Pascual T, Prat A, Brasó-Maristany F. Lorman-Carbó N, et al. Among authors: chic n. Sci Rep. 2024 Jul 11;14(1):16030. doi: 10.1038/s41598-024-67126-2. Sci Rep. 2024. PMID: 38992220 Free PMC article.
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy.
Pascual T, Fernandez-Martinez A, Agrawal Y, Pfefferle AD, Chic N, Brasó-Maristany F, Gonzàlez-Farré B, Paré L, Villacampa G, Saura C, Hernando C, Muñoz M, Galván P, Gonzàlez-Farré X, Oliveira M, Gil-Gil M, Ciruelos E, Villagrasa P, Gavilá J, Prat A, Perou CM. Pascual T, et al. Among authors: chic n. NPJ Breast Cancer. 2024 Mar 6;10(1):20. doi: 10.1038/s41523-024-00625-7. NPJ Breast Cancer. 2024. PMID: 38448600 Free PMC article.
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies.
Conte B, Brasó-Maristany F, Hernández AR, Pascual T, Villacampa G, Schettini F, Vidal Losada MJ, Seguí E, Angelats L, Garcia-Fructuoso I, Gómez-Bravo R, Lorman-Carbó N, Paré L, Marín-Aguilera M, Martínez-Sáez O, Adamo B, Sanfeliu E, Fratini B, Falato C, Chic N, Vivancos A, Villagrasa P, Staaf J, Parker JS, Perou CM, Prat A. Conte B, et al. Among authors: chic n. EBioMedicine. 2024 Apr;102:105043. doi: 10.1016/j.ebiom.2024.105043. Epub 2024 Mar 5. EBioMedicine. 2024. PMID: 38447275 Free PMC article.
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
Dieci MV, Conte P, Bisagni G, Bartolini S, Frassoldati A, Generali D, Piacentini F, Griguolo G, Tagliafico E, Brasó Maristany F, Chic N, Paré L, Miglietta F, Vicini R, D'Amico R, Balduzzi S, Prat A, Guarneri V. Dieci MV, et al. Among authors: chic n. J Natl Cancer Inst. 2024 Jan 10;116(1):69-80. doi: 10.1093/jnci/djad179. J Natl Cancer Inst. 2024. PMID: 37676829 Free PMC article.
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.
Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martinez A, González-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavilá J, Barrios CH, Lluch A, Martín M, Locci M, De Placido S, Prat A. Schettini F, et al. Among authors: chic n. NPJ Breast Cancer. 2023 Apr 29;9(1):32. doi: 10.1038/s41523-023-00538-x. NPJ Breast Cancer. 2023. PMID: 37120452 Free PMC article. No abstract available.
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis.
Schettini F, Martínez-Sáez O, Falato C, De Santo I, Conte B, Garcia-Fructuoso I, Gomez-Bravo R, Seguí E, Chic N, Brasó-Maristany F, Paré L, Vidal M, Adamo B, Muñoz M, Pascual T, Ciruelos E, Perou CM, Carey LA, Prat A. Schettini F, et al. Among authors: chic n. ESMO Open. 2023 Jun;8(3):101214. doi: 10.1016/j.esmoop.2023.101214. Epub 2023 Apr 17. ESMO Open. 2023. PMID: 37075698 Free PMC article.
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer.
Prat A, Brasó-Maristany F, Martínez-Sáez O, Sanfeliu E, Xia Y, Bellet M, Galván P, Martínez D, Pascual T, Marín-Aguilera M, Rodríguez A, Chic N, Adamo B, Paré L, Vidal M, Margelí M, Ballana E, Gómez-Rey M, Oliveira M, Felip E, Matito J, Sánchez-Bayona R, Suñol A, Saura C, Ciruelos E, Tolosa P, Muñoz M, González-Farré B, Villagrasa P, Parker JS, Perou CM, Vivancos A. Prat A, et al. Among authors: chic n. Nat Commun. 2023 Mar 1;14(1):1157. doi: 10.1038/s41467-023-36801-9. Nat Commun. 2023. PMID: 36859416 Free PMC article.
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
Fernandez-Martinez A, Pascual T, Singh B, Nuciforo P, Rashid NU, Ballman KV, Campbell JD, Hoadley KA, Spears PA, Pare L, Brasó-Maristany F, Chic N, Krop I, Partridge A, Cortés J, Llombart-Cussac A, Prat A, Perou CM, Carey LA. Fernandez-Martinez A, et al. Among authors: chic n. JAMA Oncol. 2023 Apr 1;9(4):490-499. doi: 10.1001/jamaoncol.2022.6288. JAMA Oncol. 2023. PMID: 36602784 Free PMC article. Clinical Trial.
42 results